Research Papers: Gerotarget (Focus on Aging):
Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study)
Metrics: PDF 685 views | HTML 1339 views | ?
Romain Corre1,12, Radj Gervais2, Florian Guisier3, Louis Tassy4, Florent Vinas5, Régine Lamy6, Gislaine Fraboulet7, Laurent Greillier8, Helene Doubre9, Renaud Descourt10, Christos Chouaid5 and Jean-Bernard Auliac11
1 Department of Pneumology, CHU Pontchaillou, Rennes, France
2 Pneumo-Oncology Department, Centre Francois Baclesse, Caen, France
3 Pneumology Department, CHU Hôpitaux de Rouen-Charles Nicolle, Rouen, France
4 Oncology Department, Institut Paoli-Calmette, Marseille, France
5 Pneumology Department, CH Intercommunal de Créteil, Créteil, France
6 Oncology Department, CH Sud-Bretagne, Lorient, France
7 Pneumology Department, Hôpital René-Dubos, Pontoise, France
8 Pneumo-Oncology Department, Hôpital Sainte-Marguerite, Assistance Publique-Hôpitaux de Marseille, Marseille, France
9 Pneumology Department, Hôpital Foch, Suresnes, France
10 Cancerology Institute, CHU Brest, Brest, France
11 Pneumology Department, CH François Quesnay, Mantes La Jolie, France
12 UMR INSERM U1242-COSS, Rennes University, Rennes, France
Romain Corre, email:
Keywords: targeted therapies; tyrosine-kinase inhibitors; non-small cell lung cancer; EGFR; elderly; Gerotarget
Received: September 22, 2017 Accepted: November 13, 2017 Published: January 02, 2018
Objective. To assess efficacy and tolerance of EGFR tyrosine-kinase inhibitors (TKIs) for advanced EGFR-mutated non-small cell lung cancer (NSCLC) in octogenarians.
Patients and methods. Patients aged 80 years or older with EGFR-mutated NSCLC treated by EGFR TKI between January 2011 and March 2015 whatever the line of treatment were retrospectively selected.
Results. 20 centers retrospectively included 114 patients (women, 77.2%; Caucasians, 98.3%; mean age, 83.9 years). A performance status of 0–1 or 2–3 at diagnosis was reported for 71.6% and 28.4% of patients, respectively. Overall, 95.6% of patients had adenocarcinomas and histological stage at diagnosis was stage IV for 79.8% of patients. EGFR mutations were identified mainly on exon 19 (46.5%) and exon 21 (40.4%). A geriatric assessment was performed in 35.1% of patients. TKI treatment was administered to 97.3% of patients as first or second line of treatment. Overall response rate and disease control rate were 63.3% (69/109) and 78.9% (86/109), respectively. Median progression-free survival was 11.9 months (95% confidence interval [CI], 8.6–14.7) and median overall survival was 20.9 months (95% CI, 14.3–27.1). After progression, 36/95 (37.9%) patients received a new line of chemotherapy. Main toxicities were cutaneous for 66.7% of patients (grade 3–4, 10%), diarrhea for 56.0% (grade 3–4, 15%; grade 5, 2%) and others for 25.7% (grade 3–4, 41%).
Conclusions. Octogenarians with EGFR-mutated NSCLC treated by EGFR TKI had clinical outcomes and toxicity profile comparable to younger patients. Geriatric assessment appeared to be underused in this population.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.